×
About 1,730 results

ALLMedicine™ Hypogammaglobulinemia Center

Research & Reviews  594 results

Patients with Chromosome 11q Deletions Are Characterized by Inborn Errors of Immunity I...
https://doi.org/10.1007/s10875-022-01303-8
Journal of Clinical Immunology; Huisman EJ, Brooimans AR et. al.

Jun 29th, 2022 - Disorders of the long arm of chromosome 11 (11q) are rare and involve various chromosomal regions. Patients with 11q disorders, including Jacobsen syndrome, often present with a susceptibility for bacterial and prolonged viral and fungal infection...

BCL10 loss-of-function novel mutation leading to atypical severe combined immunodeficie...
https://doi.org/10.1016/j.clim.2022.109067
Clinical Immunology (Orlando, Fla.); Al-Tamemi S, Alhinai Z et. al.

Jun 25th, 2022 - Severe combined immunodeficiency (SCID) is characterized by severe, early-onset infection in infants. B-cell lymphoma/leukemia (BCL) 10 defects causing SCID have been reported previously in two patients. A seven-month-old female infant was admitte...

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
https://clinicaltrials.gov/ct2/show/NCT00967785

Jun 24th, 2022 - Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myel...

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
https://clinicaltrials.gov/ct2/show/NCT02579967

Jun 24th, 2022 - Background: Primary immunodeficiency diseases (PIDs) are conditions associated with major quantitative or qualitative immunologic abnormalities that are, in most cases, due to defects in cells of hematopoietic origin Participants with PID can have...

see more →

Drugs  6 results see all →

Clinicaltrials.gov  41 results

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
https://clinicaltrials.gov/ct2/show/NCT02579967

Jun 24th, 2022 - Background: Primary immunodeficiency diseases (PIDs) are conditions associated with major quantitative or qualitative immunologic abnormalities that are, in most cases, due to defects in cells of hematopoietic origin Participants with PID can have...

Genetic Studies of Chronic Active Epstein-Barr Disease
https://clinicaltrials.gov/ct2/show/NCT00032513

Jun 24th, 2022 - Patients with chronic active Epstein-Barr virus (CAEBV) have (a) an illness that began as a primary infection with EBV or markedly elevated titers of antibodies to EBV, (b) histological evidence of organ disease, and (c) elevated EBV DNA levels in...

Allogeneic Hematopoietic Stem Cell Transplant for People With Primary Immunodeficiency Diseases
https://clinicaltrials.gov/ct2/show/NCT04339777

Jun 24th, 2022 - Background: With the availability of whole exome sequencing (WES) and whole genome sequencing (WGS) for patients with suspected primary immune deficiency or Primary Immune Regulatory Disorder (PIRD), the number of recognized PID s and PIRD s has i...

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
https://clinicaltrials.gov/ct2/show/NCT00967785

Jun 24th, 2022 - Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myel...

Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?
https://clinicaltrials.gov/ct2/show/NCT05357781

May 3rd, 2022 - Multiple sclerosis (MS) is the most common cause of mental and physical disability in young adults affecting approximately 10'000-15'000 persons in Switzerland (incidence 16/100000; prevalence 190/100000). MS-fatigue affects at least 75% of the MS...

see more →

News  51 results

Interstitial Granulomatous Dermatitis as an Adverse Reaction to Vedolizumab
https://www.mdedge.com/dermatology/article/252371/autoimmune-diseases/interstitial-granulomatous-dermatitis-adverse
Katherine G. Beuerlein, BS, Elise D. Martin, MD et. al.

Mar 3rd, 2022 - The number of monoclonal antibodies developed for therapeutic use has rapidly expanded over the last decade due to their generally favorable adverse effect (AE) profiles and efficacy. 1 Tumor necrosis factor α inhibitors and general integrin antago.

Second CAR T-Cell Therapy Approved for Myeloma
https://www.medpagetoday.com/hematologyoncology/myeloma/97437

Mar 1st, 2022 - The FDA approved ciltacabtagene autoleucel (cilta-cel; Carvykti), the second chimeric antigen receptor (CAR) T-cell therapy for adults with relapsed or refractory multiple myeloma, Janssen Pharmaceuticals announced. Ciltacabtagene autoleucel, a B-...

Zanubrutinib sBLA for Waldenström Macroglobulinemia Accepted in China
https://www.onclive.com/view/zanubrutinib-sbla-for-waldenstr-m-macroglobulinemia-accepted-in-china

Jan 21st, 2022 - The China National Medical Products Administration (NMPA) has accepted a supplemental new drug application (sNDA) for zanubrutinib (Brukinsa) as a treatment for adult patients with Waldenström macroglobulinemia.1 The application is supported by...

FDA Approval Sought for Teclistamab for Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/fda-approval-sought-for-teclistamab-for-relapsed-refractory-multiple-myeloma

Dec 29th, 2021 - A biologics license application seeking the approval of the off-the-shelf, T-cell redirecting bispecific antibody, teclistamab (JNJ-64007957), for use in patients with relapsed or refractory multiple myeloma has been submitted to the FDA.1 The ap...

Kahl Weighs the Complexities of Treatment Selection in Indolent Lymphoma
https://www.onclive.com/view/kahl-weighs-the-complexities-of-treatment-selection-in-indolent-lymphoma

Oct 6th, 2021 - Brad S. Kahl, MD Optimizing treatment for patients with indolent non-Hodgkin lymphoma (iNHL) has become a challenge as the frontline and recurrent treatment settings continue to evolve, said Brad S. Kahl, MD. "The management of [recurrent] indol...

see more →